• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于治疗血液透析患者甲癣的丙烯酸聚合物特比萘芬:一项II期临床试验。

Terbinafine in acrylic polymer for the treatment of onychomycosis in hemodialysis patients: a phase II clinical trial.

作者信息

Bersano Jeanne Marie Queiroz Borges, Cordeiro Matheus Gobbo, Sciani Juliana Mozer, Tescarollo Iara Lúcia, Marson Fernando Augusto Lima

机构信息

Laboratory of Molecular Biology and Genetics, Health Sciences Postgraduate Program, São Francisco University, Bragança Paulista, Brazil.

Laboratory of Clinical and Molecular Microbiology, Health Sciences Postgraduate Program, São Francisco University, Bragança Paulista, Brazil.

出版信息

Front Med (Lausanne). 2024 Nov 26;11:1417985. doi: 10.3389/fmed.2024.1417985. eCollection 2024.

DOI:10.3389/fmed.2024.1417985
PMID:39659625
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11628268/
Abstract

INTRODUCTION

Onychomycosis is a nail infection caused by dermatophyte fungi, non-dermatophyte fungi, and yeast. Patients with chronic kidney disease on dialysis are part of the population that presents higher rates of this disease, mainly due to immunosuppression. Among patients with chronic kidney disease on dialysis, the treatment of onychomycosis is complex, mainly due to the limitations imposed by comorbidities. In this context, the study evaluated the safety and potential efficacy of a treatment that combines nail debridement with the use of acrylic gel nails carrying terbinafine at a concentration of 2%.

METHODS

Patients from the Hemodialysis Center of the São Francisco de Assis University Hospital in Bragança Paulista, São Paulo, Brazil were included. Those had hallux onychomycosis with clinical forms whose treatment involved the need for nail debridement. After the debridement procedure, a nail prosthesis made with acrylic reconstruction gel and 2% terbinafine was applied. The procedure was renewed every 2 weeks (~14 days) for 11 months. The evolution was monitored with measurements of the normal-appearing nail plate and photographs. Direct mycological examination and fungal culture were performed at the beginning of the study and 30 days after applications were interrupted. Assessment of clinical response, clinical cure, mycological cure, and complete cure was performed at the end of the study. All participants answered a questionnaire about their perception of the treatment.

RESULTS

Out of the 155 patients on hemodialysis, 64/155 (41.3%) individuals were identified with symptoms suggestive of onychomycosis in the halluces after clinical analysis. Among them, 35/64 (54.7%) individuals presented a positive direct mycological examination and underwent fungal culture to identify the etiological agent. In this group of patients, 24/35 (68.6%) individuals who presented clinical forms whose treatment involved the need for nail debridement were selected. Only 15/24 (62.5%) individuals completed the study. Among the study participants, 5/15 (33.3%) still presented positive fungal culture in the presence of a negative direct mycological examination and 1/15 (6.7%) presented a positive direct mycological examination, but with a negative culture. Among those with a positive fungal culture, 3/15 (20.0%) participants presented microorganisms different from those isolated in the initial exams. Regarding cure, 5/15 (33.3%) participants showed a clinical response, 4/15 (26.7%) clinical cure, and 3/15 (20.0%) complete cure. No patient presented an allergic reaction or local irritation caused by the material used in the treatment. There were accidental superficial ulcerations caused by the electric sandpaper; however, no wound developed secondary infection. No participant reported discomfort due to the nail prosthesis use, 3/15 (20.0%) reported a feeling of discomfort caused by the vibration of the electric file and 12/15 (80.0%) reported the perception that their nails had a better appearance during treatment with nail prosthesis made with acrylic reconstruction gel and 2% terbinafine.

CONCLUSION

The application of 2% terbinafine in acrylic reconstruction gel for the manufacture of nail prostheses applied after debridement of moderate and severe forms of onychomycosis showed low efficacy as an isolated treatment in patients on dialysis due to chronic kidney disease. On the other hand, most patients had a good perception of the appearance of their nails during treatment, even when it did not result in apparent clinical improvement or complete cure.

摘要

引言

甲癣是一种由皮肤癣菌、非皮肤癣菌和酵母菌引起的指甲感染。接受透析的慢性肾脏病患者是该病发病率较高的人群之一,主要原因是免疫抑制。在接受透析的慢性肾脏病患者中,甲癣的治疗较为复杂,主要是由于合并症带来的限制。在此背景下,本研究评估了一种将指甲清创术与使用含2%特比萘芬的丙烯酸凝胶指甲相结合的治疗方法的安全性和潜在疗效。

方法

纳入巴西圣保罗布拉干萨保利斯塔圣弗朗西斯科德阿西斯大学医院血液透析中心的患者。这些患者患有拇趾甲癣,临床症状表明治疗需要进行指甲清创术。清创术后,应用由丙烯酸重建凝胶和2%特比萘芬制成的指甲假体。该操作每2周(约14天)重复一次,持续11个月。通过测量外观正常的指甲板和拍照来监测病情进展。在研究开始时以及应用中断30天后进行直接真菌学检查和真菌培养。在研究结束时评估临床反应、临床治愈、真菌学治愈和完全治愈情况。所有参与者回答了一份关于他们对治疗看法的问卷。

结果

在155名血液透析患者中,经临床分析,64/155(41.3%)的个体在拇趾出现了提示甲癣的症状。其中,35/64(54.7%)的个体直接真菌学检查呈阳性,并接受真菌培养以确定病原体。在这组患者中,选择了24/35(68.6%)临床症状表明治疗需要进行指甲清创术的个体。只有15/24(62.5%)的个体完成了研究。在研究参与者中,5/15(33.3%)在直接真菌学检查为阴性的情况下真菌培养仍呈阳性,1/15(6.7%)直接真菌学检查呈阳性,但培养为阴性。在真菌培养呈阳性的患者中,3/15(20.0%)的参与者分离出的微生物与初始检查不同。关于治愈情况,5/15(33.3%)的参与者有临床反应,4/15(26.7%)临床治愈,3/15(20.0%)完全治愈。没有患者因治疗所用材料出现过敏反应或局部刺激。电砂纸导致了意外的浅表溃疡;然而,没有伤口发生继发感染。没有参与者报告因使用指甲假体感到不适,3/15(20.0%)报告因电动锉刀的振动感到不适,12/15(80.0%)报告在用由丙烯酸重建凝胶和2%特比萘芬制成的指甲假体治疗期间,感觉指甲外观更好。

结论

在清创术后应用含2%特比萘芬的丙烯酸重建凝胶制作指甲假体来治疗中重度甲癣,对于因慢性肾脏病接受透析的患者而言,作为一种单一治疗方法疗效较低。另一方面,大多数患者在治疗期间对指甲外观的感觉良好,即使治疗并未带来明显的临床改善或完全治愈。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fbc/11628268/2d48c1d73fdf/fmed-11-1417985-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fbc/11628268/0a444bce7cb4/fmed-11-1417985-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fbc/11628268/b6f9589227b5/fmed-11-1417985-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fbc/11628268/b455309db3fc/fmed-11-1417985-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fbc/11628268/a2f4f0c3b25f/fmed-11-1417985-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fbc/11628268/f64e5f8ae5c0/fmed-11-1417985-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fbc/11628268/1d4b62b4ea0e/fmed-11-1417985-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fbc/11628268/07e4cbb9d3f4/fmed-11-1417985-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fbc/11628268/a2d4e35c901d/fmed-11-1417985-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fbc/11628268/2d48c1d73fdf/fmed-11-1417985-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fbc/11628268/0a444bce7cb4/fmed-11-1417985-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fbc/11628268/b6f9589227b5/fmed-11-1417985-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fbc/11628268/b455309db3fc/fmed-11-1417985-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fbc/11628268/a2f4f0c3b25f/fmed-11-1417985-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fbc/11628268/f64e5f8ae5c0/fmed-11-1417985-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fbc/11628268/1d4b62b4ea0e/fmed-11-1417985-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fbc/11628268/07e4cbb9d3f4/fmed-11-1417985-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fbc/11628268/a2d4e35c901d/fmed-11-1417985-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fbc/11628268/2d48c1d73fdf/fmed-11-1417985-g009.jpg

相似文献

1
Terbinafine in acrylic polymer for the treatment of onychomycosis in hemodialysis patients: a phase II clinical trial.用于治疗血液透析患者甲癣的丙烯酸聚合物特比萘芬:一项II期临床试验。
Front Med (Lausanne). 2024 Nov 26;11:1417985. doi: 10.3389/fmed.2024.1417985. eCollection 2024.
2
Oral antifungal medication for toenail onychomycosis.用于治疗趾甲甲癣的口服抗真菌药物。
Cochrane Database Syst Rev. 2017 Jul 14;7(7):CD010031. doi: 10.1002/14651858.CD010031.pub2.
3
Prevalence and risk predictors of onychomycosis in patients on hemodialysis: an observation, prospective, and unicenter study in Brazil.血液透析患者甲癣的患病率及风险预测因素:巴西的一项观察性、前瞻性单中心研究
Front Med (Lausanne). 2023 Nov 23;10:1268324. doi: 10.3389/fmed.2023.1268324. eCollection 2023.
4
A multicentre, randomised, parallel-group, double-blind, vehicle-controlled and open-label, active-controlled study (versus amorolfine 5%), to evaluate the efficacy and safety of terbinafine 10% nail lacquer in the treatment of onychomycosis.一项多中心、随机、平行分组、双盲、阳性药对照、开放性、自身对照研究(对比阿莫罗芬 5%),旨在评估特比萘芬 10% 指甲油治疗甲真菌病的疗效和安全性。
Mycoses. 2022 Apr;65(4):392-401. doi: 10.1111/myc.13392. Epub 2021 Dec 6.
5
Onychomycosis due to Neoscytalidium treated with oral terbinafine, ciclopirox nail lacquer and nail abrasion: a pilot study of 25 patients.甲真菌病由 Neoscytalidium 引起,经口服特比萘芬、环吡酮甲涂剂和甲锉治疗:25 例患者的初步研究。
Mycopathologia. 2013 Feb;175(1-2):75-82. doi: 10.1007/s11046-012-9580-5. Epub 2012 Sep 14.
6
Safety and efficacy of oral terbinafine in the treatment of onychomycosis: analysis of the elderly subgroup in Improving Results in ONychomycosis-Concomitant Lamisil and Debridement (IRON-CLAD), an open-label, randomized trial.口服特比萘芬治疗甲癣的安全性和有效性:在开放性随机试验“改善甲癣治疗结果——特比萘芬与清创术联用(IRON-CLAD)”中老年亚组分析
Am J Geriatr Pharmacother. 2006 Mar;4(1):1-13. doi: 10.1016/j.amjopharm.2005.12.012.
7
Topical and device-based treatments for fungal infections of the toenails.用于治疗趾甲真菌感染的局部和基于器械的疗法。
Cochrane Database Syst Rev. 2020 Jan 16;1(1):CD012093. doi: 10.1002/14651858.CD012093.pub2.
8
A randomized trial of amorolfine 5% solution nail lacquer combined with oral terbinafine compared with terbinafine alone in the treatment of dermatophytic toenail onychomycoses affecting the matrix region.一项关于5%阿莫罗芬溶液甲涂剂联合口服特比萘芬与单用特比萘芬治疗累及甲母质区的皮肤癣菌性 toenail 甲真菌病的随机试验。 (注:toenail 直译为“脚趾甲”,这里结合语境可能是想说“趾甲”,但按照要求未做修改)
Br J Dermatol. 2000 Jun;142(6):1177-83. doi: 10.1046/j.1365-2133.2000.03545.x.
9
Single-blind, randomized, prospective study on terbinafine and itraconazole for treatment of dermatophyte toenail onychomycosis in the elderly.特比萘芬和伊曲康唑治疗老年人皮肤癣菌性 toenail 甲真菌病的单盲、随机、前瞻性研究。 (注:这里“toenail”结合语境应是指趾甲,但表述稍显奇怪,可能原文有误,正常应该是“toenail onychomycosis”即趾甲甲真菌病)
J Am Acad Dermatol. 2001 Mar;44(3):479-84. doi: 10.1067/mjd.2001.110874.
10
Efficacy and safety of a new medicated nail hydrolacquer in the treatment of adults with toenail onychomycosis: A randomised clinical trial.一种新型药物指甲水溶胶治疗成人趾甲甲真菌病的疗效和安全性:一项随机临床试验。
Mycoses. 2023 Jul;66(7):566-575. doi: 10.1111/myc.13543. Epub 2022 Nov 17.

引用本文的文献

1
Onychomycosis in Diabetics: A Common Infection with Potentially Serious Complications.糖尿病患者的甲癣:一种常见感染,伴有潜在严重并发症
Life (Basel). 2025 Aug 13;15(8):1285. doi: 10.3390/life15081285.

本文引用的文献

1
Congenital nail abnormalities.先天性指甲异常。
Hand Surg Rehabil. 2024 Apr;43S:101527. doi: 10.1016/j.hansur.2023.01.011.
2
The prevalence of onychomycosis in patients with chronic renal failure undergoing dialysis: A cross-sectional study.接受透析的慢性肾衰竭患者甲癣的患病率:一项横断面研究。
Heliyon. 2024 Feb 11;10(4):e25737. doi: 10.1016/j.heliyon.2024.e25737. eCollection 2024 Feb 29.
3
Impact of onychomycosis on the quality of life of patients.甲癣对患者生活质量的影响。
Curr Med Mycol. 2023 Jun;9(2):39-44. doi: 10.18502/cmm.2023.345062.1430.
4
Effectiveness and safety of oral terbinafine for dermatophyte distal subungual onychomycosis.口服特比萘芬治疗皮肤癣菌远端甲下型甲真菌病的有效性和安全性。
Expert Opin Pharmacother. 2024 Jan-Apr;25(1):15-23. doi: 10.1080/14656566.2024.2305304. Epub 2024 Feb 1.
5
Onychomycosis.甲真菌病。
Hand Surg Rehabil. 2024 Apr;43S:101638. doi: 10.1016/j.hansur.2024.101638. Epub 2024 Jan 11.
6
Medication Associations With Severe Cutaneous Adverse Reactions: A Case/Non-Case Analysis Using the FDA Adverse Event Reporting System.药物与严重皮肤不良反应的关联:使用美国食品药品监督管理局不良事件报告系统进行的病例/非病例分析
J Cutan Med Surg. 2024 Jan-Feb;28(1):51-58. doi: 10.1177/12034754231220931. Epub 2024 Jan 8.
7
Prevalence and risk predictors of onychomycosis in patients on hemodialysis: an observation, prospective, and unicenter study in Brazil.血液透析患者甲癣的患病率及风险预测因素:巴西的一项观察性、前瞻性单中心研究
Front Med (Lausanne). 2023 Nov 23;10:1268324. doi: 10.3389/fmed.2023.1268324. eCollection 2023.
8
The safety of oral antifungals for the treatment of onychomycosis.口服抗真菌药物治疗甲真菌病的安全性。
Expert Opin Drug Saf. 2023 Jul-Dec;22(12):1169-1178. doi: 10.1080/14740338.2023.2280137. Epub 2023 Dec 18.
9
On the Basis of Sex: Impact and Treatment of Toenail Onychomycosis in Female Patients.基于性别:女性患者趾甲甲真菌病的影响与治疗
J Clin Aesthet Dermatol. 2023 Oct;16(10):52-57.
10
Risk factors for the development of tinea pedis and onychomycosis: Real-world evidence from a single-podiatry center, large-scale database in Japan.足癣和甲真菌病发展的危险因素:来自日本单一足病中心、大规模数据库的真实世界证据。
J Dermatol. 2024 Jan;51(1):30-39. doi: 10.1111/1346-8138.16991. Epub 2023 Oct 30.